source
- Jupiter Neurosciences signs $100M deal for U.S. rights to PharmAla's MDMA therapy ALA-002Jupiter Neurosciences announced a licensing agreement with Canadian biotech PharmAla Biotech to obtain U.S. rights to an MDMA‑based drug, ALA‑002, aimed at treating neuropsychiatric conditions. Th…
- Rare-disease biotech coalition urges Trump admin to carve out orphan drugs from Medicare price-cut pilotsBiotech firms formed the Rare Disease Company Coalition and met with the White House Office of Management and Budget to discuss excluding orphan drugs from two Medicare price‑cut pilot programs. T…